Lung Cancer Clinical Trial

A Study of Ganetespib in Subjects With ALK-Positive Non-Small-Cell Lung Cancer (NSCLC)

Summary

Phase 2 study of subjects with ALK positive, advanced NSCLC who have failed up to 3 prior therapies. The study will take place globally at multiple study centers. Subjects will be enrolled to receive ganetespib one time per week for three weeks followed by a rest week; and will repeat this schedule until the cancer gets worse or the subject is unable to tolerate ganetespib. The primary goal of the study is to determine how ganetespib is tolerated and how active it is in ALK positive NSCLC.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Males or females aged 18 years or older
Pathological confirmation of advanced NSCLC
Evidence of a translocation or an inversion event involving the ALK gene locus
ECOG Performance Status 0 or 1

Exclusion Criteria:

Prior therapy with ALK-targeted agents
Prior treatment with Hsp90 inhibitor
Known EGFR activating mutation
Presence of active or untreated central nervous system (CNS) metastases

Study is for people with:

Lung Cancer

Phase:

Phase 2

Estimated Enrollment:

12

Study ID:

NCT01562015

Recruitment Status:

Completed

Sponsor:

Synta Pharmaceuticals Corp.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 5 Locations for this study

See Locations Near You

Synta Pharmaceuticals Investigative Site
Tampa Florida, 33612, United States
Synta Pharmaceuticals Investigative Site
Cleveland Ohio, 44195, United States
Synta Pharmaceuticals Investigative Site
Hamilton Ontario, ON L8, Canada
Synta Pharmaceuticals Investigative Site
Ottawa Ontario, K1H 8, Canada
Synta Pharmaceuticals Investigative Site
Toronto Ontario, M5G 2, Canada

How clear is this clinincal trial information?

Study is for people with:

Lung Cancer

Phase:

Phase 2

Estimated Enrollment:

12

Study ID:

NCT01562015

Recruitment Status:

Completed

Sponsor:


Synta Pharmaceuticals Corp.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.